Is optimal first-line chemotherapy deliverable in all newly diagnosed ovarian cancers? A population-based study

O. M. McNally (Lead / Corresponding author), E. Delaney, R. D. Petty, M. E. Cruickshank, A. W. Hutcheon, D. E. Parkin

Research output: Contribution to journalArticle

7 Citations (Scopus)


NICE guidance recommends the use of paclitaxel and a platinum therapy for all cases of ovarian cancer. We report our experience of treating 133 patients with ovarian cancer over a 3-year period. Where indicated, 91% received chemotherapy. A taxane/platinum combination was found to be appropriate in 63% of patients only.

Original languageEnglish
Pages (from-to)966-967
Number of pages2
JournalBritish Journal of Cancer
Issue number6
Publication statusPublished - 15 Sep 2003



  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Combined Modality Therapy
  • Female
  • Humans
  • Middle Aged
  • Mixed Tumor, Mullerian
  • Neoplasm Staging
  • Neoplasms, Glandular and Epithelial
  • Ovarian Neoplasms
  • Paclitaxel
  • Practice Guidelines as Topic
  • Prospective Studies
  • Radiotherapy Dosage
  • Survival Rate
  • Taxoids

Cite this